EMEAReolysin could possibly qualify under the European orphan drug program. And Europe has a larger population base than the US.
"The EMEA's "Orphan Medicinal Product Designation" is designed to promote the development of drugs which may provide significant benefit to patients suffering from rare diseases identified as "life-threatening or very serious." Under EMEA guidelines, Orphan Medicinal Product Designation provides 10 years of potential market exclusivity if the product candidate is approved for marketing in the European Union. Orphan status also permits EMEA assistance in optimizing the candidate's clinical development through participation in designing the clinical protocol and preparing the marketing application. Additionally, a drug candidate designated by the EMEA as an Orphan Medicinal Product may qualify for a reduction in regulatory fees as well as a European Union-funded research grant. "